2.18
11.27%
-0.31
Cyclacel Pharmaceuticals Inc stock is currently priced at $2.18, with a 24-hour trading volume of 374.37K.
It has seen a -11.27% decreased in the last 24 hours and a +0.89% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.69 pivot point. If it approaches the $1.98 support level, significant changes may occur.
Previous Close:
$2.49
Open:
$2.37
24h Volume:
374.37K
Market Cap:
$2.86M
Revenue:
-
Net Income/Loss:
$-22.56M
P/E Ratio:
-1.1295
EPS:
-1.93
Net Cash Flow:
$-16.12M
1W Performance:
+46.32%
1M Performance:
+0.89%
6M Performance:
+280.28%
1Y Performance:
+301.71%
Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile
Name
Cyclacel Pharmaceuticals Inc
Sector
Industry
Phone
908 517 7330
Address
200 Connell Drive, Suite 1500, Berkeley Heights, NJ
Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-18-22 | Resumed | Oppenheimer | Outperform |
Apr-27-20 | Resumed | ROTH Capital | Buy |
Sep-07-18 | Initiated | Ladenburg Thalmann | Buy |
Oct-16-15 | Initiated | H.C. Wainwright | Buy |
Feb-04-10 | Initiated | Roth Capital | Buy |
Oct-28-09 | Initiated | Merriman | Buy |
Aug-12-08 | Initiated | Piper Jaffray | Buy |
Mar-12-08 | Reiterated | Cantor Fitzgerald | Buy |
Mar-12-08 | Reiterated | Collins Stewart | Buy |
Mar-12-08 | Reiterated | Needham & Co | Buy |
Nov-27-07 | Reiterated | Cantor Fitzgerald | Buy |
Aug-10-07 | Reiterated | Cantor Fitzgerald | Buy |
Jun-04-07 | Reiterated | Needham & Co | Buy |
Apr-23-07 | Initiated | Lazard Capital | Buy |
Apr-10-07 | Initiated | Cantor Fitzgerald | Buy |
View All
Cyclacel Pharmaceuticals Inc Stock (CYCC) Latest News
Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
GlobeNewswire Inc.
Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
GlobeNewswire Inc.
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
GlobeNewswire Inc.
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire Inc.
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire Inc.
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
GlobeNewswire Inc.
Cyclacel Pharmaceuticals Inc Stock (CYCC) Financials Data
Cyclacel Pharmaceuticals Inc (CYCC) Net Income 2024
CYCC net income (TTM) was -$22.55 million for the quarter ending December 31, 2023, a -6.40% decrease year-over-year.
Cyclacel Pharmaceuticals Inc (CYCC) Cash Flow 2024
CYCC recorded a free cash flow (TTM) of -$16.12 million for the quarter ending December 31, 2023, a +22.64% increase year-over-year.
Cyclacel Pharmaceuticals Inc (CYCC) Earnings per Share 2024
CYCC earnings per share (TTM) was -$26.75 for the quarter ending December 31, 2023, a +6.63% growth year-over-year.
About Cyclacel Pharmaceuticals Inc
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
Cap:
|
Volume (24h):